Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1619305 | 0.98 | FUCA1 (0.49) | FUCA1SIGMAR1ALDH1A1TDP1DRD4 | |
| SCHEMBL60509 | 0.84 | FUCA1 (0.55) | FUCA1SIGMAR1ALDH1A1DRD4S1PR1 | |
| SCHEMBL12187772 | 0.84 | FUCA1 (0.55) | FUCA1SIGMAR1ALDH1A1DRD4S1PR1 | |
| SCHEMBL5316806 | 0.83 | SLC6A3 (0.47) | SIGMAR1DRD2GBA1 | |
| Hydrochloric Acid SCHEMBL11836687 | 0.82 | FUCA1 (0.53) | FUCA1SIGMAR1ALDH1A1DRD4S1PR1 | |
| SCHEMBL477142 | 0.80 | FUCA1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| SCHEMBL653224 | 0.80 | FUCA1 (0.55) | FUCA1SIGMAR1S1PR1S1PR5DRD2 | |
| SCHEMBL3120195 | 0.80 | USP2 (0.49) | SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL5540770 | 0.79 | FUCA1 (0.50) | FUCA1SIGMAR1ALDH1A1DRD4S1PR1 | |
| SCHEMBL4669302 | 0.79 | FUCA1 (0.50) | FUCA1SIGMAR1ALDH1A1TDP1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| EP-2536730-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-07-08 | — | — | EP | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-8957074-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2015-02-17 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-6559143-B1 | Class III electrophysiological activity, drugs which prolong the trans-membrane action potential duration and refractoriness, without affecting cardiac conduction | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| WO-2002083687-A1 | 3,7-DIAZYBICYCLO [3.3.1] FORMULATIONS AS ANTIARRHYTMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083689-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTI-ARRYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083688-A1 | 3,7-DIAZABICYCLO [3.3.1] FORMULATIONS AS ANTIARHYTHMIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083690-A1 | NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002083691-A1 | NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-10-24 | — | — | WO | disclosed |
| EP-1235831-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2002028863-A1 | NEW OXABISPIDINE COMPOUND USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2002028864-A1 | NEW PROCESS FOR THE PRODUCTION OF OXABISPIDINES | ASTRAZENECA AB (SE) | 2002-04-11 | — | — | WO | disclosed |
| WO-2001028992-A2 | NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | FUCA1 3824/4885SIGMAR1 3859/4885ALDH1A1 1115/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | FUCA1 3920/4885SIGMAR1 3883/4885ALDH1A1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.